PDSB - PDS Biotech is on the rise as H.C. Wainwright sees multiple catalysts ahead

Photo by luismmolina/E+ via Getty Images After losing more than a quarter of value yesterday, the shares of PDS Biotechnology ([[PDSB]] +17.6%) have rebounded today in reaction to encouraging Phase 2 data presented at the 2021 ASCO Annual Meeting for PDS0101 in human papillomavirus ((HPV))-associated cancers. At eight months, 58% (7/12) of patients who received PDS0101 in combination with bintrafusp alfa (M7824) and NHS-IL12 (M9241) had tumor reduction with an overall objective response rate ((ORR)) of 42% (5/12). A complete response was observed in one patient. H.C. Wainwright analyst Joseph Pantginis predicts important drivers for shares thanks to multiple catalysts linked to all three Phase 2 studies on PDS0101. “We remind investors that all three PDS0101 important Phase 2 studies are now ongoing and readouts are expected in 2021/early 2022,” Pantginis wrote. A few days ago, PDS Biotech announced a protocol amendment to expand its Phase 2 VERSATILE-002 study that is

For further details see:

PDS Biotech is on the rise as H.C. Wainwright sees multiple catalysts ahead